Premium
Cell‐surface serglycin promotes adhesion of myeloma cells to collagen type I and affects the expression of matrix metalloproteinases
Author(s) -
Skliris Antonis,
Labropoulou Vassiliki T.,
Papachristou Dionysios J.,
Aletras Alexios,
Karamanos Nikos K.,
Theocharis Achilleas D.
Publication year - 2013
Publication title -
the febs journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.981
H-Index - 204
eISSN - 1742-4658
pISSN - 1742-464X
DOI - 10.1111/febs.12179
Subject(s) - matrix metalloproteinase , multiple myeloma , chemistry , cell adhesion , type i collagen , adhesion , proteoglycan , cell , bone marrow , cell culture , microbiology and biotechnology , extracellular matrix , cancer research , immunology , biology , biochemistry , endocrinology , genetics , organic chemistry
Serglycin ( SG ) is mainly expressed by hematopoetic cells as an intracellular proteoglycan. Multiple myeloma cells constitutively secrete SG , which is also localized on the cell surface in some cell lines. In this study, SG isolated from myeloma cells was found to interact with collagen type I ( C ol I ), which is a major bone matrix component. Notably, myeloma cells positive for cell‐surface SG (cs SG ) adhered significantly to C ol I , compared to cells lacking cs SG . Removal of cs SG by treatment of the cells with chondroitinase ABC or blocking of cs SG by an SG ‐specific polyclonal antibody significantly reduced the adhesion of myeloma cells to C ol I . Significant up‐regulation of expression of the matrix metalloproteinases MMP –2 and MMP –9 at both the m RNA and protein levels was observed when culturing cs SG ‐positive myeloma cells on C ol I ‐coated dishes or in the presence of soluble C ol I . MMP –9 and MMP –2 were also expressed in increased amounts by myeloma cells in the bone marrow of patients with multiple myeloma. Our data indicate that cs SG of myeloma cells affects key functional properties, such as adhesion to C ol I and the expression of MMP s, and imply that cs SG may serve as a potential prognostic factor and/or target for pharmacological interventions in multiple myeloma.